• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics, Inc. - Warrant (NQ:DRMAW)

0.0200 UNCHANGED
Streaming Delayed Price Updated: 2:45 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,595
Open 0.0200
Bid (Size) 0.0158 (30)
Ask (Size) 0.0190 (24)
Prev. Close 0.0200
Today's Range 0.0200 - 0.0201
52wk Range 0.0082 - 0.0440
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
July 08, 2025
Via ACCESS Newswire
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 14, 2025
Via ACCESS Newswire

Performance

YTD
+35.1%
+35.1%
1 Month
+20.5%
+20.5%
3 Month
+49.3%
+49.3%
6 Month
-32.4%
-32.4%
1 Year
+1.5%
+1.5%

More News

Read More
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
April 15, 2025
Via ACCESS Newswire
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
March 27, 2025
Via ACCESS Newswire
Dermata to Present on BioPub on January 31, 2025
January 29, 2025
Via ACCESS Newswire
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
December 16, 2024
Via ACCESSWIRE
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
December 10, 2024
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
March 17, 2025
Via ACCESS Newswire
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
February 25, 2025
Via ACCESS Newswire
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
January 22, 2025
Via ACCESS Newswire
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
January 21, 2025
Via ACCESS Newswire
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
December 03, 2024
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 13, 2024
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 07, 2024
Via ACCESSWIRE
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
July 17, 2024
Via ACCESSWIRE
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
November 11, 2024
From Virtual Investor Conferences
Via GlobeNewswire
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
October 08, 2024
Via ACCESSWIRE
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
September 17, 2024
Via ACCESSWIRE
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
September 16, 2024
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 15, 2024
Via ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on April 3, 2024
March 27, 2024
Via ACCESSWIRE
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
September 05, 2024
Via ACCESSWIRE
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
May 17, 2024
Via ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on February 7, 2024
February 01, 2024
Via ACCESSWIRE
Why Dermata Therapeutics Stock Took Off After-Hours
January 04, 2024
Via Benzinga

Frequently Asked Questions

Is Dermata Therapeutics, Inc. - Warrant publicly traded?
Yes, Dermata Therapeutics, Inc. - Warrant is publicly traded.
What exchange does Dermata Therapeutics, Inc. - Warrant trade on?
Dermata Therapeutics, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Dermata Therapeutics, Inc. - Warrant?
The ticker symbol for Dermata Therapeutics, Inc. - Warrant is DRMAW on the Nasdaq Stock Market
What is the current price of Dermata Therapeutics, Inc. - Warrant?
The current price of Dermata Therapeutics, Inc. - Warrant is 0.0200
When was Dermata Therapeutics, Inc. - Warrant last traded?
The last trade of Dermata Therapeutics, Inc. - Warrant was at 08/01/25 02:45 PM ET
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap